Risk of dementia in gout and hyperuricaemia: a meta-analysis of cohort studies

Shu-Yue Pan, Rui-Juan Cheng, Zi-Jing Xia, Qiu-Ping Zhang, Yi Liu

ABSTRACT

Objectives Gout, characterised by hyperuricaemia with monosodium urate crystal formation and inflammation, is the most common inflammatory arthritis in adults. Recent studies have found that elevated uric acid levels are related to the occurrence of dementia. We conducted a study to investigate the association between dementia and gout or hyperuricaemia.

Design Systematic review and meta-analysis of cohort studies.

Data sources Studies were screened from inception to 28 June 2019 by searching Medline, Embase and the Cochrane Library databases.

Eligibility criteria Cohort studies comparing the risk of dementia in patients with gout and hyperuricaemia versus non-gout and non-hyperuricaemia controls were enrolled.

Data extraction and analysis Two reviewers separately selected studies and extracted data using the Medical Subject Headings without restriction on languages or countries. The adjusted HRs were pooled using the DerSimonian and Laird random effects model. Sensitivity analyses were conducted to evaluate the stability of the results. Publication bias was evaluated using Egger’s and Begg’s tests. Quality assessment was performed according to the Newcastle-Ottawa Scale.

Results Four cohort studies that met the inclusion criteria were included in our meta-analysis. We found that gout and hyperuricaemia did not increase the risk of dementia, with a pooled HR of 0.94 (95% CI 0.69 to 1.28), but might decrease the risk of Alzheimer’s disease (AD), with a pooled HR of 0.78 (95% CI 0.64 to 0.95). There was little evidence of publication bias. Quality assessment of the included studies was high (range: 6–8 points).

Conclusions Our study shows that gout and hyperuricaemia do not increase the risk of dementia. However, gout and hyperuricaemia might have a protective effect against AD. Due to the limited number of research articles, more investigations are needed to demonstrate the potential relationship between dementia and gout or hyperuricaemia.

INTRODUCTION

With the ageing of the population and the improvement in living standards, the incidence of age-related cerebrovascular diseases and metabolic diseases is increasing. Dementia is a common age-dependent disorder characterised by progressive deterioration of cognitive ability and function, which can be caused by primary neurological, neuropsychiatric and other conditions, such as traumatic brain injury and tumours. Most senile dementias are caused by neurodegeneration. Common diseases include Alzheimer’s disease (AD), vascular dementia (VD), Lewy body dementia, frontotemporal degeneration and Parkinson’s disease. Notably, the number of patients with dementia worldwide is expected to increase to 115 million by 2050. Therefore, it is essential to study the pathogenesis of dementia to improve the prevention and treatment of this condition.

With changes in diet and increases in obesity, the incidence of hyperuricaemia also continues to rise. Hyperuricaemia is caused by increased production of uric acid in and/or decreased excretion of uric acid from the body. Hyperuricaemia may not cause obvious clinical symptoms for a long time, but with a persistent increase in blood uric acid levels, urate deposition may occur, which can damage tissues and internal organs. In fact, hyperuricaemia causes gout and is an independent risk factor for cardiovascular disease and chronic kidney disease. Gout is the most common inflammatory arthritis in adults. Common hallmarks of gout include hyperuricaemia, monosodium urate crystal formation and gouty arthritis.
Moreover, several epidemiological studies have reported an association between chronic inflammation and dementia. In recent years, blood uric acid levels have been considered to be closely related to neurodegenerative changes in Parkinson’s disease and AD. Many studies have evaluated the relationship between uric acid and cognitive impairment disorders. The findings of studies have evaluated the relationship between uric acid and cognitive impairment disorders. The findings of studies have evaluated the relationship between uric acid and cognitive impairment disorders. The findings of studies have evaluated the relationship between uric acid and cognitive impairment disorders. The findings of Lu et al supported the potential neuroprotective function of uric acid. In contrast, Schretlen et al found that elevated blood uric acid levels increased the risk of cognitive impairment. Thus, whether uric acid predisposes to or protects against dementia remains unclear.

Thus, we here performed a systematic review and meta-analysis of the data reported by cohort studies on the association between dementia and gout or hyperuricaemia.

METHODS

A comprehensive literature search was conducted to identify all relevant articles in the Medline (Ovid), Embase (Ovid) and Cochrane Library databases from their respective inception dates until 28 June 2019. Two independent reviewers searched the databases systemically and extensively to obtain studies about the association between dementia and gout or hyperuricaemia, without any language or country restrictions. The Medical Subject Headings terms ‘gout’, ‘hyperuricaemia’ and ‘dementia’ were used in the search strategy (see online supplemental file 1).

Data abstraction was performed by two independent reviewers using a unified form. From each primary study, we extracted the following information: the first author’s last name, year of publication, country where the study was performed, sample size, mean age, proportion of men, diagnostic criteria, subtype of dementia, average duration of follow-up years, adjusted covariates, quality of assessment and adjusted HR and 95% CI.

The quality of the studies was scored according to the Newcastle-Ottawa Scale, where a higher score (≥5 points) represents better quality. Three major components were scored: selection (0–4 points), comparability (0–2 points) and outcome (0–3 points).

Inclusion and exclusion criteria

Two investigators read the titles and abstracts of all identified papers and evaluated the literature eligibility independently. Then, we obtained full reports from the articles that appeared eligible, and two investigators again independently assessed whether the papers met the following inclusion criteria: (1) cohort study; (2) original, peer-reviewed study; (3) risk estimates of dementia morbidity in patients with gout or hyperuricaemia compared with non-gout or non-hyperuricaemia controls, with dementia occurring after gout or hyperuricaemia; (4) adjusted HR can be extracted or calculated; and (5) clearly stated dementia (any type, including VD and AD), gout and hyperuricaemia diagnostic criteria; and (6) if multiple studies were reported from the same centre and using the same patient population, we selected the study with the largest sample size or with the most comprehensive data for the meta-analysis. The following reports were excluded: (1) conference articles, review articles, editorials, commentaries, hypothesis papers, case reports and letters; (2) multiple publications from the same population; (3) studies without a control group; (4) studies without clear definition of hyperuricaemia, gout or dementia; and (5) studies with dementia occurring before the onset of gout or hyperuricaemia.

Statistical analysis

Review Manager V.5.3 software was used to calculate the pooled effect size estimate. The adjusted HRs were pooled using the DerSimonian and Laird random effects model, and the weights were equal to the inverse variance of each study’s effect estimation. Forest plots were produced for visual assessment of the HRs and corresponding 95% CIs across studies. Heterogeneity of HRs across studies was evaluated using the Cochrane Q statistic and the I² statistic (values of 25%, 50% and 75% were considered to represent low, medium and high heterogeneity, respectively). Sensitivity analysis was conducted to evaluate the stability of the results. Publication bias was evaluated using Egger’s and Begg’s tests.

RESULTS

A flow diagram of the selection process is presented in figure 1. A total of 740 potentially relevant articles were identified by keyword search from the electronic databases. After the initial screening based on titles and abstracts, 665 articles were excluded. Full-text evaluation was conducted in the remaining 75 articles, and 71 articles were excluded due to irrelevant topics or because of being case–control, review or meta-analysis reports, or because of not fulfilling our inclusion criteria. Ultimately, four cohort studies were selected for the meta-analysis.
The characteristics of the included studies are shown in Table 1. All four studies included both men and women, and the average age of participants was ≥60 years. These studies were conducted primarily in the UK, USA, Taiwan, China and France. The study samples ranged from 406 to 1,712,821, and the follow-up durations ranged from 2.3 to 12 years. We used the Newcastle-Ottawa Scale to assess the quality of individual studies. In short, a maximum of 9 points was assigned to each study: 4 for selection, 2 for comparability and 3 for outcomes. A final score >5 points was regarded as high quality. The quality of studies was good, ranging from 6 to 8 points.

We used Egger’s (p=0.41) and Begg’s (p=1.00) tests to test the publication bias, and there was no statistical evidence of publication bias among the studies. We performed a sensitivity analysis by changing the analysis model from a random effects model to a fixed effects model, and found that the results were unstable for different analysis models, giving different results. When using the random effects model, we found that gout or hyperuricaemia did not increase the risk of dementia, with a pooled HR of 0.94 (95% CI 0.69 to 1.28). Using the fixed effects model, we found that gout or hyperuricaemia increased the risk of dementia, with a pooled HR of 1.07 (95% CI 1.04 to 1.10). In consideration of the high heterogeneity of the included articles, we preferred the results given by the random effects model.

In our meta-analysis, we found no increased risk of dementia among patients with gout or hyperuricaemia, with a pooled HR of 0.94 (95% CI 0.69 to 1.28), with an I² of 98%, p<0.001 (figure 2). However, there was a decreased risk of AD in patients with gout or hyperuricaemia, with a pooled HR of 0.78 (95% CI 0.64 to 0.95), with an I² of 55%, p=0.01 (figure 3).

Lu et al and Latourte et al analysed the patients with dementia in European populations, Singh and Cleveland14 analysed the patients in North America and Hong et al10 investigated the data of Asian populations. Lu et al used AD diagnostic codes, which were positively predicted at 83% in a UK-based GPRD-based validation study. Singh and Cleveland and Hong et al used the International Classification of Diseases, Ninth Revision, Clinical

### Table 1 Characteristics of included studies in the meta-analysis

<table>
<thead>
<tr>
<th></th>
<th>Lu et al8</th>
<th>Singh and Cleveland et al14</th>
<th>Hong et al10</th>
<th>Latourte et al9</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Country</strong></td>
<td>USA</td>
<td>Taiwan, China</td>
<td>France</td>
<td></td>
</tr>
<tr>
<td><strong>Study design</strong></td>
<td>Cohort study</td>
<td>Cohort study</td>
<td>Cohort study</td>
<td></td>
</tr>
<tr>
<td><strong>Year</strong></td>
<td>2016</td>
<td>2018</td>
<td>2015</td>
<td>2018</td>
</tr>
<tr>
<td><strong>Age, mean years</strong></td>
<td>65</td>
<td>75.2</td>
<td>63.5</td>
<td>72.9</td>
</tr>
<tr>
<td><strong>Male (%)</strong></td>
<td>71</td>
<td>42.6</td>
<td>63</td>
<td>38.7</td>
</tr>
<tr>
<td><strong>Diagnosis of gout or hyperuricaemia</strong></td>
<td>Diagnostic code using the Read classification</td>
<td>ICD-9-CM codes</td>
<td>ICD-9-CM codes</td>
<td>Hyperuricaemia: ≥360 µmol/L for men, ≥300 µmol/L for women</td>
</tr>
<tr>
<td><strong>Diagnosis of dementia</strong></td>
<td>AD diagnostic codes</td>
<td>ICD-9-CM codes</td>
<td>ICD-9-CM codes</td>
<td>DSM-IV, NINCDS-ADRA</td>
</tr>
<tr>
<td><strong>Subtype of dementia</strong></td>
<td>AD</td>
<td>All subtypes of dementia</td>
<td>All subtypes of dementia</td>
<td>All subtypes of dementia</td>
</tr>
<tr>
<td><strong>Number of dementias with controls</strong></td>
<td>309/238 805</td>
<td>106 346/1 416 173</td>
<td>5905/114 742</td>
<td>AD: 102/114 742</td>
</tr>
<tr>
<td><strong>Number of dementias with cases</strong></td>
<td>1942/59 224</td>
<td>5310/296 648</td>
<td>1214/28 769</td>
<td>AD: 542/28 769</td>
</tr>
<tr>
<td><strong>Adjusted confounders</strong></td>
<td>Age, gender, entry time, BMI, smoking, alcohol use, physician visits, social deprivation index, comorbidities and medication use</td>
<td>Age, gender, race, medical comorbidities, common medications for cardiac diseases and gout</td>
<td>Age, gender, relevant comorbidities</td>
<td>Age, gender, tobacco and alcohol consumption, cholesterol, medical comorbidities, medication use</td>
</tr>
<tr>
<td><strong>Follow-up years (mean or mean±SD)</strong></td>
<td>5</td>
<td>2.3 (1.7)</td>
<td>4.3 (2.1)</td>
<td>12</td>
</tr>
<tr>
<td><strong>Quality grading</strong></td>
<td>7 points</td>
<td>6 points</td>
<td>7 points</td>
<td>8 points</td>
</tr>
</tbody>
</table>

AD, Alzheimer’s disease; BMI, body mass index; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Version IV; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; NINCDS-ADRA, National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association; VD, vascular dementia.
Modification as the diagnostic criterion for dementia. Latourte et al used the Diagnostic and Statistical Manual of Mental Disorders, Version IV criteria for the diagnosis of dementia and the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association as the diagnostic standard for AD. We consider that the reasons for the high degree of heterogeneity are related to the differences between races, diets, climate factors, clinical characteristics between different countries, lack of standardized design, inclusion criteria and uniform follow-up time, which may affect the final result universality.

**DISCUSSION**

This meta-analysis was based on four articles of cohort studies performed in different countries, thus providing a comprehensive evaluation of the association between dementia and gout or hyperuricaemia. The four cohort studies analysed 121 136 cases of dementia, of which Lu et al included only patients with AD, while the other three analysed data on all types of dementia. In addition, of the four articles included in our meta-analysis, only one described a lower risk of developing VD in patients with gout. All studies were assessed as being of high quality based on the Newcastle-Ottawa Scale. The included studies had adjustments for other risk factors. Our meta-analysis showed no statistically significant risk of dementia in patients with gout or hyperuricaemia compared with the non-gout or non-hyperuricaemia controls. In contrast, gout or hyperuricaemia was negatively correlated with the risk of AD. The existing reports hold different views on the pathophysiological mechanism of the relationship between gout and dementia. Whether a high uric acid level has predisposed to or protects against dementia has not been uniformly summarised. Several studies have indicated that inflammatory pathways may play an important role in increasing the risk of dementia. Hyperuricaemia causes persistent systemic inflammation of gout and can also affect the inflammatory capacity of immune cells. However, there has been no unified conclusion about the relationship between dementia and gout or hyperuricaemia, which prompted our meta-analysis.

To date, it has been controversial whether gout or hyperuricaemia and dementia are related. There have been several speculations about the mechanism by which gout could affect the onset of dementia. Some reports propose that gout or hyperuricaemia may increase the risk of dementia because chronic inflammation from gout has some effects on the brain. Some studies have suggested that high inflammatory cytokine levels in brains with neurodegeneration play important roles in the pathogenesis of dementia. Others have suggested that gout is associated with oxidative stress, which may play a key role in the pathogenesis of dementia. Elevated inflammatory cytokines can damage endothelial cells, activate inflammatory cells and cause oxidative stress, which promotes the progression of atherosclerosis. Atherosclerotic cardiovascular diseases are well-established risk factors for dementia. Additionally, there has been some evidence that an association of hyperuricaemia with cardiovascular disease is due to concomitant oxidative stress. Taken together, chronic inflammation and oxidative stress may be the final pathways in dementia and gout or hyperuricaemia, which may explain the high risk of dementia reported by some studies in elderly people with gout or hyperuricaemia.

In contrast, some studies have confirmed that gout or hyperuricaemia may decrease the risk of dementia. Uric acid has been proposed to have both a pro-oxidant effect and an antioxidant effect. It can have some pro-oxidant effects in its oxidised state, but there is relatively little evidence that this is an important mechanism for circulating uric acid, in comparison to its antioxidant role. Uric acid is well established as an important...
circulating antioxidant and free radical scavenger. It is an antioxidant and metal chelator in vitro. It can effectively clear peroxynitrite and hydroxyl radicals and reduce oxidative stress as an antioxidant, and may exert possible neuroprotective effects. Moreover, it has been reported that the pathogenesis of AD is related to mitochondrial dysfunction. Some studies have shown that uric acid might preserve mitochondrial function and suppress oxyradical accumulation, thereby inhibiting the cytotoxic activity of lactoperoxidase and repairing free radical-induced DNA damage. Scheepers et al reported that a lower level of serum urate may lead to a higher risk of dementia since antioxidant capacity might be reduced with the decreasing of the urate concentration among middle-aged women. They surveyed and followed up 1462 women aged 38–60 years over 44 years and found that a higher serum urate may have a protective effect on dementia including AD andVD. Euser et al investigated that high serum urate levels are associated with a reduced risk of dementia and further improved cognitive function. In a recent study, Liu et al came to the same conclusion that a lower level of uric acid is associated with AD in Chinese. In our study, we analysed the AD subgroup of dementia and found that gout can reduce the risk of AD. This may also confirm the neuroprotective role of uric acid. Unlike asymptomatic hyperuricaemia, patients with gout receive anti-inflammatory or urate-lowering therapies, and it cannot be excluded that those drugs will affect the risk of dementia. Pandey et al reported that a urate-lowering drug benz bromarone can antagonise oxidative stress and improve the function of vascular endothelial cells, which may be related to the reduced probability of dementia in patients with gout. However, it is not yet fully clear whether antigout drugs can reduce the incidence of dementia and more research will enable us to understand the effects of antigout drugs on dementia.

Our study found no correlation between dementia and gout or hyperuricaemia. Dementia involves variable clinical symptoms, multiple subtypes and complex pathogenesis, which may explain the contradictory results of studies on gout or hyperuricaemia. More research is needed to support this viewpoint. The risk of AD is inversely proportional to gout, and the neuroprotective mechanism of uric acid may play a dominant role in the pathogenesis of AD.

However, there were some potential limitations to our study. First, there were only four studies in our meta-analysis, whose numbers of articles included were relatively small. Moreover, the cohort studies were mostly medical registry-based studies, which would raise concerns over coding inaccuracy and misclassification. Second, although studies included had been adjusted for other risk factors, the statistical heterogeneity is still high, which might be attributed to differences in demographics, dietary factors, environmental factors and clinical characteristics in different countries, or lack of standardised design, inclusion criteria and follow-up time. Third, this was a pooled analysis of observational studies, which could only demonstrate an association, but not causality. Therefore, we cannot determine the impact of gout, hyperuricaemia or other unknown confounding factors on the outcome of dementia risk. Moreover, in the sensitivity analysis, we found that the results were unstable when using different analysis models. Considering the high heterogeneity of the included articles, we preferred the results given by the random effects model. Consequently, caution is needed when interpreting the present meta-analysis findings.

In conclusion, our meta-analysis of cohort studies suggested that there is no risk of dementia among patients with gout and hyperuricaemia. However, high uric acid levels have a protective effect on AD. More investigations are needed to demonstrate the potential relationship between dementia and patients with gout and hyperuricaemia.


Appendix 1

Medline Ovid Search Strategy

1. exp Dementia/
2. Delirium/
3. Wernicke Encephalopathy/
4. Delirium, Dementia, Amnestic, Cognitive Disorders/
5. dement*.mp.
6. alzheimer*.mp.
7. (lewy* adj2 bod*).mp.
8. deliri*.mp.
9. (chronic adj2 cerebrovascular).mp.
10. (organic brain disease or organicbrain syndrome).mp
11. (normal pressure hydrocephalus andshunt*).mp.
12. benign senescent forgetfulness.mp.
13. (cerebr* adj2 deteriorat*).mp.
14. (cerebral* adj2 insufficient*).mp.
15. (pick* adj2 disease).mp.
16. (creutzfeldt or jcd or cjd).mp.
17. huntington*.mp.
18. binswanger*.mp.
19. korsako*.mp.
20.1-19/OR
21. exp gout/
22. gout.mp.
23. exp hyperuricemia /
24. uric acid.mp.
25. 20-23/OR
26. 20 and 25

Appendix 2

Embase search strategy
1. exp gout/
2. gout.mp.
3. exp hyperuricemia /
4. uric acid.mp.
5.1-4/OR
6. exp *dementia/
7. dement*.ti,ab.
8. alzheimer*.ti,ab.
9. (lewy* adj2 bod*).ti,ab.
10. (frontotemporal* or FTD or FTLD).ti,ab.
11.6-10/or
12. 5 and 11
Appendix 3

Cochrane library search strategy

1. exp gout /

2. gout.mp.

3. exp hyperuricemia /

4. uric acid.mp.

5.1-4/OR

6. exp *dementia/

7. dement*.ti,ab.

8. alzheimer*.ti,ab.

9. (lewy* adj2 bod*).ti,ab.

10. (frontotemporal* or FTD or FTLD).ti,ab.

11.6-10/or

12. 5 and 11